Predicting the risk of cardiovascular disease in HIV-infected patients: The Data collection on Adverse Effects of Anti-HIV Drugs Study

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 17, Issue 5, 2010, Pages 491-501

  Friis Møller, Nina ^a   Thiébaut, Rodolphe ^b   Reiss, Peter ^d   Weber, Rainer ^e   Monforte, Antonella D'Arminio ^f   De Wit, Stephane ^g   El Sadr, Wafaa ^h   Fontas, Eric ^c   Worm, Signe ^a   Kirk, Ole ^a   Phillips, Andrew ⁱ   Sabin, Caroline A ⁱ   Lundgren, Jens D ^a   Law, Matthew G ^j  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b INSERM   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d STICHTING HIV MONITORING   (Netherlands)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY OF MILAN   (Italy)

^g SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^h Howard Hughes Medical Institute   (United States)

ⁱ ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

Antiretroviral drugs; cardiovascular risk; HIV; prediction model

Indexed keywords

ABACAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LOPINAVIR PLUS RITONAVIR;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENDER; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; SMOKING; SYSTOLIC BLOOD PRESSURE;

EID: 78049258742     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJR.0b013e328336a150     Document Type: Article

References (45)

1. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-2486.
2. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747-1748.
3. Iloeje U, Yuan Y, L'Italien G, Mauskopf J, Holmberg S, Moorman A, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6:37-44.
4. The D:A:D Study group. Risk of myocardial infarction in association with different classes of antiretroviral drugs. N Engl J Med 2007; 356:1723-1735.
5. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-1426.
6. Strategies for Management of Anti-Retroviral Therapy/INSIGHT and DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
7. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in HIV patients exposed to specific antiretroviral drugs from the three major drug classes: the D:A:D study. J Infect Dis 2009; 201:318-330.
8. Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, d'Arminio MA, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006; 7:218-230.
9. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
10. The D:A:D Study group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
11. D'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004; 18:1811-1817.
12. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90:583-612.
13. WHO MONICA Project. MONICA Manual, part IV, Event Registration. [Accessed 28 October 2009], at (http:/www.ktl.fi/publications/monica/manual/part4/iv-1. htm). 1999.
14. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. (abstract #43LB) Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4. Montreal, Canada: 16th Conference on Retroviruses and Opportunistic Infections; 2009.
15. Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, Hatano H, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23:2021-2027.
16. Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-1601.
17. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006; 368:647-658.
18. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007; 370:1829-1839.
19. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
20. Chirovsky DR, Fedirko V, Cui Y, Sazonov V, Barter P. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. Eur J Cardiovasc Prev Rehabil 2009; 16:404-423.
21. Thomsen T. HeartScore: a new web-based approach to European cardiovascular disease risk management. Eur J Cardiovasc Prev Rehabil 2005; 12:424-426.
22. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121(1 Pt 2):293-298.
23. De Visser CL, Bilo HJ, Thomsen TF, Groenier KH, Meyboom-de Jong B. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med 2003; 253:553-562.
24. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286:180-187.
25. Royston P, Parmar MK, Sylvester R. Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Stat Med 2004; 23:907-926.
26. May M, Royston P, Egger M, Justice AC, Sterne JA. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med 2004; 23:2375-2398.
27. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-2512.
28. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, Gerstoft J. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44:1625-1631.
29. Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis 2005; 181:93-100.
30. Thomsen TF, McGee D, Davidsen M, Jorgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002; 31:817-822.
31. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio MA, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-1193.
32. Benard A, Tessier JF, Rambeloarisoa J, Bonnet F, Fossoux H, Neau D, et al. HIV infection and tobacco smoking behaviour: prospects for prevention? ANRS CO3 Aquitaine Cohort, 2002. Int J Tuberc Lung Dis 2006; 10:378-383.
33. Patel N, Talwar A, Reichert VC, Brady T, Jain M, Kaplan MH. Tobacco and HIV. Clin Occup Environ Med 2006; 5:193-207, xi.
34. Effros RB. From Hayflick to Walford: the role of T cell replicative senescence in human aging. Exp Gerontol 2004; 39:885-890.
35. Worm SW, De WS, Weber R, Sabin CA, Reiss P, El-Sadr W, et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of Anti-HIV Drugs (D:A:D Study). Circulation 2009; 119:805-811.
36. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991; 265:627-631.
37. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.
38. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 2000; 23:962-968.
39. Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007; 45:1074-1081.
40. May M, Sterne JA, Shipley M, Brunner E, d'Agostino R, Whincup P, et al. A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol 2007; 36:1309-1318.
41. Kristoffersen US, Kofoed K, Kronborg G, Benfield T, Kjaer A, Lebech AM. Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy. HIV Med 2009; 10:627-633.
42. Friis-Moller N, Thiebaut R, Reiss P, El-Sadr W, Worm S, Kirk O, et al. (abstract 808) Predicting the Risk of Coronary Heart Disease in HIV-infected Patients: The D:A:D Risk Equation. Los Angeles: 14th Conference on Retroviruses and Opportunistic Infections; 2007.
43. Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, d'Arminio MA, Hermans P, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis 2002; 185:178-187.
44. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368:451-458.
45. Lundgren JD, Battegay M, Behrens G, De WS, Guaraldi G, Katlama C, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9:72-81.